keyword
MENU ▼
Read by QxMD icon Read
search

Nonalcoholic steatohepatitis

keyword
https://www.readbyqxmd.com/read/28526997/nafld-as-a-sexual-dimorphic-disease-role-of-gender-and-reproductive-status-in-the-development-and-progression-of-nonalcoholic-fatty-liver-disease-and-inherent-cardiovascular-risk
#1
REVIEW
Stefano Ballestri, Fabio Nascimbeni, Enrica Baldelli, Alessandra Marrazzo, Dante Romagnoli, Amedeo Lonardo
Nonalcoholic fatty liver disease (NAFLD) spans steatosis through nonalcoholic steatohepatis, cirrhosis, and hepatocellular carcinoma (HCC) associated with striking systemic features and excess cardiovascular and liver-related mortality. The pathogenesis of NAFLD is complex and multifactorial. Endocrine derangements are closely linked with dysmetabolic traits. For example, in animal and human studies, female sex is protected from dysmetabolism thanks to young individuals' ability to partition fatty acids towards ketone body production rather than very low density lipoprotein (VLDL)-triacylglycerol, and to sex-specific browning of white adipose tissue...
May 19, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28518142/mir-130a-3p-attenuates-activation-and-induces-apoptosis-of-hepatic-stellate-cells-in-nonalcoholic-fibrosing-steatohepatitis-by-directly-targeting-tgfbr1-and-tgfbr2
#2
Yang Wang, Jinghua Du, Xuemin Niu, Na Fu, Rongqi Wang, Yuguo Zhang, Suxian Zhao, Dianxing Sun, Yuemin Nan
Nonalcoholic fibrosing steatohepatitis is a uniform process that occurs throughout nonalcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) have been shown to be involved in the biological processes, but the role and molecular mechanism of miRNAs in NAFLD are not entirely clear. In this study, we observed a significant reduction in the expression of miR-130a-3p in livers of a mouse model with fibrosis induced by a methionine-choline-deficient diet, of NAFLD patients, and in activated hepatic stellate cells (HSCs)...
May 18, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28512251/inhibition-of-the-cell-death-pathway-in-non-alcoholic-steatohepatitis-nash-related-hepatocarcinogenesis-is-associated-with-histone-h4-lysine-16-deacetylation
#3
Aline de Conti, Kostiantyn Dreval, Volodymyr Tryndyak, Orish Ebere Orisakwe, Sharon Ross, Frederick Beland, Igor P Pogribny
Hepatocellular carcinoma (HCC) is one of the most aggressive human cancers and its incidence is steadily increasing worldwide. Recent epidemiological findings have suggested that the increased incidence of HCC is associated with obesity, type 2 diabetes mellitus, and nonalcoholic steatohepatitis (NASH); however, the mechanisms and the molecular pathogenesis of NASH-related HCC are not fully understood. In order to elucidate the underlying mechanisms of the development of NASH-related HCC, we investigated the hepatic transcriptomic and histone modification profiles in Stelic Animal Model (STAM) mice, the first animal model of NASH-related HCC to resemble the disease pathogenesis in humans...
May 16, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28511439/light-chain-myeloma-induced-severe-hypertriglyceridemia
#4
Shafeeque Rahman, Prabhat Kumar, Subodh Kumar Mahto, Rajinder Singh Tonk, Rajesh S Taneja
Hyperlipidemia is very common in general population and incidence has further increased in recent years. Evaluation of patient presenting with lipid disorders is essential to obtain a definite diagnosis to prevent complications, and apply the most appropriate treatment. An isolated elevation in triglyceride levels may be caused by a primary disorder of lipid metabolism like familial hypertriglyceridemia. It may also arise secondary to a number of conditions like diabetes mellitus, alcohol intake, hypothyroidism, drugs, infections and nephrotic syndrome...
March 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28511168/-the-nonalcoholic-steatohepatitis-influence-on-the-course-and-progression-of-ischemic-heart-disease
#5
Ігор М Скрипник, Ольга В Щербак, Ганна С Маслова
INTRODUCTION: Nonalcoholic steatohepatitis (NASH) can be considered a risk factor of progression of diseases associated with atherosclerosis, especially ischemic heart disease (IHD) with a high probability of early myocardial infarction (MI). AIM: To study the peculiarities and nature of ischemic heart disease clinical picture in patients with concomitant NASH. MATERIALS AND METHODS: The study involved 58 patients with ischemic heart disease...
2017: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28511161/-the-diagnostics-and-clinical-pattern-of-nonalcoholic-fatty-liver-disease-in-patients-with-pre-diabetes-and-type-2-diabetes-and-obesity
#6
Ксенія І Чубірко
INTRODUCTION: The data of epidemiological researches confirm the tendency in increasing of non alcoholic fatty liver disease (NAFLD) in patients with insulin resistance which occurs because of obesity, diabetes type 2 and metabolic syndrome. AIM: Optimization of diagnostic and treatment efficacy in patients with non alcoholic steatosis and steatohepatitis on the background of obesity. MATERIALS AND METHODS: General clinical examination of patients, laboratory and instrumental methods ( fatty liver index, non invasive assessment of liver, morphology, electrocardiography, treadmillergometry, ultrasound examination of abdominal organs, liver elastography,CT,MRI, methods of statistical analysis...
2017: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28511152/-pathogenetic-substantiation-of-complex-treatment-of-nonalcoholic-steatohepatitis-and-steatosis-in-patients-with-pre-diabetes-and-type-2-diabetes
#7
Іван В Чопей, Віталіна В Івачевська, Ксенія І Чубірко, Тарас І Гряділь, Михайло М Гечко
INTRODUCTION: Thesis is devoted to the optimization of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes by acting on carbohydrate and lipid metabolism as well as providing hepatoprotection. AIM: Optimization of diagnostics and treatment in patients treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes. MATERIAL AND METHODS: Examination and treatment of 117 patients with NAFLD and pre-diabetes and type 2 diabetes was performed...
2017: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28503559/cell-free-dna-methylation-as-liquid-biopsy-for-the-assessment-of-fibrosis-in-patients-with-nonalcoholic-steatohepatitis-a-gap-between-innovation-and-implementation
#8
EDITORIAL
Silvia Sookoian, Carlos J Pirola
No abstract text is available yet for this article.
April 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28502444/nonalcoholic-fatty-liver-disease-in-children-hepatic-and-extrahepatic-complications
#9
REVIEW
Praveen Kumar Conjeevaram Selvakumar, Mohammad Nasser Kabbany, Valerio Nobili, Naim Alkhouri
Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome and has become the most common form of chronic liver disease in children and adolescents. The histologic spectrum of NAFLD is broad ranging, from the relatively benign form of simple steatosis to the aggressive form of nonalcoholic steatohepatitis, eventually leading to fibrosis and cirrhosis. NAFLD has also been recognized as an independent risk factor for extrahepatic complications, such as cardiovascular disease, type 2 diabetes mellitus, sleep disorders, and osteoporosis...
June 2017: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/28489136/hyperferritinemia-in-patients-with-nonalcoholic-fatty-liver-disease
#10
Raffaelle K Barros, Helma Pinchemel Cotrim, Carla H Daltro, Yanaihara A Oliveira
Objective: In liver diseases, hyperferritinemia (HYF) is related to injured cells in acquired and genetic conditions with or without iron overload. It is frequent in patients with nonalcoholic fatty liver disease (NAFLD), in which it is necessary to define the mean of HYF to establish the better approach for them. The present study evaluated the significance of elevated ferritin in patients with NAFLD and steatohepatitis (NASH). Method: The review was performed using search instruments of indexed scientific material, including MEDLINE (by PubMed), Web of Science, IBECS and LILACS, to identify articles published in Portuguese, English and Spanish, from 2005 to May, 2016...
March 2017: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/28487615/urinary-metabolomics-analysis-identifies-key-biomarkers-of-different-stages-of-nonalcoholic-fatty-liver-disease
#11
Shu Dong, Zong-Ying Zhan, Hong-Yan Cao, Chao Wu, Yan-Qin Bian, Jian-Yuan Li, Gen-Hong Cheng, Ping Liu, Ming-Yu Sun
AIM: To identify a panel of biomarkers that can distinguish between non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and explore molecular mechanism involved in the process of developing NASH from NAFLD. METHODS: Biomarkers may differ during stages of NAFLD. Urine and blood were obtained from non-diabetic subjects with NAFLD and steatosis, with normal liver function (n = 33), from patients with NASH, with abnormal liver function (n = 45), and from healthy age and sex-matched controls (n = 30)...
April 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28487605/changes-in-human-hepatic-metabolism-in-steatosis-and-cirrhosis
#12
Zoe Schofield, Michelle Ac Reed, Philip N Newsome, David H Adams, Ulrich L Günther, Patricia F Lalor
AIM: To understand the underlying metabolic changes in human liver disease we have applied nuclear magnetic resonance (NMR) metabolomics analysis to human liver tissue. METHODS: We have carried out pilot study using (1)H-NMR to derive metabolomic signatures from human liver from patients with steatosis, nonalcoholic steatohepatitis (NASH) or alcohol-related liver damage (ARLD) to identify species that can predict outcome and discriminate between alcohol and metabolic-induced liver injuries...
April 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28486870/long-term-cardiac-morbidity-and-mortality-in-patients-with-aortic-valve-disease-following-liver-transplantation-a-case-matching-study
#13
Ramona Nicolau-Raducu, Thomas Marshall, Hamang Patel, Kelly Ural, Joseph Koveleskie, Susan Smith, Donald Ganier, Bryan Evans, Brian Fish, William Daly, Ari J Cohen, George Loss, Amjad Bokhari, Bobby Nossaman
INTRODUCTION: This retrospective study examined the role of aortic valve (AV) disease in patients who underwent orthotopic liver transplantation (OLT) to determine the incidence of postoperative cardiac morbidity and mortality when compared with a matched control group without AV disease. METHODS: Patients were included in the AV group if diagnosed with aortic stenosis (AS) or aortic regurgitation or had received AV replacement prior to OLT. The AV group (n = 53) was matched to a control group (n = 212) with the following preoperative variables: type of organ transplanted, age, gender, race, body mass index, MELD, redo-transplantation, preoperative renal replacement therapy, nonalcoholic steatohepatitis, viral hepatitis, diabetes, and coronary artery disease...
May 1, 2017: Seminars in Cardiothoracic and Vascular Anesthesia
https://www.readbyqxmd.com/read/28484191/epidemiology-and-risk-factors-of-nonalcoholic-fatty-liver-disease-nafld-and-nonalcoholic-steatohepatitis-nash
#14
Ryosuke Tateishi, Kazuhiko Koike
No abstract text is available yet for this article.
2017: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/28480218/magnetic-resonance-elastography-shear-wave-velocity-correlates-with-liver-fibrosis-and-hepatic-venous-pressure-gradient-in-adults-with-advanced-liver-disease
#15
Ahmed M Gharib, Ma Ai Thanda Han, Eric G Meissner, David E Kleiner, Xiongce Zhao, Mary McLaughlin, Lindsay Matthews, Bisharah Rizvi, Khaled Z Abd-Elmoniem, Ralph Sinkus, Elliot Levy, Christopher Koh, Robert P Myers, G Mani Subramanian, Shyam Kottilil, Theo Heller, Joseph A Kovacs, Caryn G Morse
Background. Portal hypertension, an elevation in the hepatic venous pressure gradient (HVPG), can be used to monitor disease progression and response to therapy in cirrhosis. Since obtaining HVPG measurements is invasive, reliable noninvasive methods of assessing portal hypertension are needed. Methods. Noninvasive markers of fibrosis, including magnetic resonance elastography (MRE) shear wave velocity, were correlated with histologic fibrosis and HVPG measurements in hepatitis C (HCV) and/or HIV-infected patients with advanced liver disease enrolled in a clinical trial of treatment with simtuzumab, an anti-LOXL2 antibody...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28475150/reply-to-the-letter-to-the-editor-by-li-et-al-bioinformatics-analysis-in-mice-with-diet-induced-nonalcoholic-steatohepatitis-treated-with-astaxanthin-and-vitamin-e
#16
Masuko Kobori, Yumiko Takahashi, Mutsumi Sakurai, Yinhua Ni, Guanliang Chen, Mayumi Nagashimada, Shuichi Kaneko, Tsuguhito Ota
n/a.
May 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28474143/cirrhosis-patients-with-nonalcoholic-steatohepatitis-are-significantly-less-likely-to-receive-surveillance-for-hepatocellular-carcinoma
#17
Hesam Tavakoli, Ann Robinson, Benny Liu, Taft Bhuket, Zobair Younossi, Sammy Saab, Aijaz Ahmed, Robert J Wong
BACKGROUND: Disparities in receipt of hepatocellular carcinoma (HCC) surveillance contribute to disparities in overall survival outcomes. AIM: We aim to evaluate disparities in receipt of routine HCC surveillance among patients with cirrhosis in a large urban safety-net hospital. METHODS: Consecutive adults (age ≥ 18) with cirrhosis from July 1, 2014, to December 31, 2015, were retrospectively evaluated to determine rates of receiving appropriate HCC surveillance within 6 months and 1 year after diagnosis of cirrhosis...
May 4, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28472039/cytokeratin-18-and-uric-acid-predicts-disease-severity-in-taiwanese-nonalcoholic-steatohepatitis-patients
#18
Jee-Fu Huang, Ming-Lun Yeh, Chung-Feng Huang, Ching-I Huang, Pei-Chien Tsai, Chi-Ming Tai, Hua-Ling Yang, Chia-Yen Dai, Meng-Hsuan Hsieh, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang
BACKGROUND & AIMS: Identification of disease severity remains a challenge in the management of non-alcoholic steatohepatitis (NASH). Cytokeratin-18 (CK18), is a recently developed non-invasive biomarker for NASH. We aimed to assess the performance of CK18 in disease severity prediction among Taiwanese NASH patients. METHODS: A total of 76 biopsy-proven NASH patients (54 males, age = 41.0 ± 13.5 years) were consecutively recruited. The optimal cutoff values of CK18 for each stage of fibrosis were correlated with their histopathological manifestations...
2017: PloS One
https://www.readbyqxmd.com/read/28470881/concentration-dependent-response-to-pioglitazone-in-nonalcoholic-steatohepatitis
#19
M Kawaguchi-Suzuki, F Bril, S Kalavalapalli, K Cusi, R F Frye
BACKGROUND: Pioglitazone is a safe and effective option to manage patients with type 2 diabetes and nonalcoholic steatohepatitis (NASH). However, there is marked variability in treatment response. AIM: To evaluate the relationship between concentrations of pioglitazone and its active metabolites and treatment outcomes in patients with NASH. METHODS: Pioglitazone concentrations were measured in patients with NASH treated with pioglitazone 45 mg/day for 18 months; liver biopsy samples were obtained at baseline and after treatment...
May 3, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28470676/acetyl-coa-carboxylase-inhibition-reduces-de-novo-lipogenesis-in-overweight-male-subjects-a-randomized-double-blind-crossover-study
#20
Kathryn Stiede, Wenyan Miao, Heather S Blanchette, Carine Beysen, Geraldine Harriman, H James Harwood, Heather Kelley, Rosana Kapeller, Tess Schmalbach, William F Westlin
NDI-010976, an allosteric inhibitor of acetyl-CoA carboxylases (ACC) ACC1 and ACC2, reduces hepatic de novo lipogenesis (DNL) and favorably affects steatosis, inflammation, and fibrosis in animal models of fatty liver disease. This study was a randomized, double-blind, placebo-controlled, crossover trial evaluating the pharmacodynamic effects of a single oral dose of NDI-010976 on hepatic DNL in overweight and/or obese, but otherwise healthy, adult male subjects. Subjects were randomized to receive either NDI-010976 (20, 50, or 200 mg) or matching placebo in Period 1, followed by the alternate treatment in Period 2, and hepatic lipogenesis was stimulated with oral fructose administration...
May 3, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
keyword
keyword
5882
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"